At a glance
ClinicalIndex Comparison RecordPhase 2Active· 4 enrolled
Drug / intervention
Acalabrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib for Autoimmune Hemolytic Anemia and 3 related conditions. Active but no longer recruiting, targeting 4 participants across 1 site.
Detailed Summary
This phase II trial studies the effect of acalabrutinib in treating autoimmune hemolytic anemia that has come back (relapsed) or has not responded to previous treatment (refractory) in patients with chronic lymphocytic leukemia. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2Active
2021202220232024202520262027
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionApr 2023
TodayJul 2026
Study CompletionFeb 2027
First PostedDec 8, 2020
Enrollment StartMar 16, 2021
Primary CompletionApr 1, 2023
Study CompletionFeb 8, 2027
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.6 years ago
Interventions
Acalabrutinibdrug
Given PO